{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:49:52Z","timestamp":1785847792447,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy of methotrexate (MTX) therapy and identify clinical and laboratory predictors of treatment failure, particularly in relatively contraindicated cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included 225 hemodynamically stable patients with ectopic pregnancy treated with MTX between January 2019 and December 2024 at a tertiary university hospital. Relatively contraindicated cases were defined as having one or more of the following: \u03b2-hCG\u2009\u2265\u20095000\u00a0IU\/L, ectopic mass\u2009\u2265\u20094\u00a0cm, fetal cardiac activity, or pelvic free fluid\u2009\u2265\u20095\u00a0cm. 58 patients met these criteria, while 167 were MTX-indicated. All patients received a single-dose intramuscular MTX protocol (50\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      on day 0), and serum \u03b2-hCG levels were measured on days 0, 4, and 7. Treatment success was defined as a decline of \u03b2-hCG to\u2009&lt;\u20095\u00a0mIU\/mL without surgical intervention. Predictive factors for treatment failure were analyzed using logistic regression. Based on the identified independent predictors, a preliminary scoring model was constructed to explore risk stratification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall MTX success rate was 85.8%. Success was significantly higher in the indicated group (92.8%) than in the relatively contraindicated group (65.5%). In the latter, treatment failure was significantly associated with higher baseline \u03b2-hCG levels and the pelvic free fluid\u2009\u2265\u20095\u00a0cm in the pouch of douglas. Multivariate analysis identified a significant association between these factors and MTX failure (\u03b2-hCG: OR 7.44, p\u2009&lt;\u20090.001; free fluid: OR 4.10, p\u2009=\u20090.022). Other parameters, including fetal cardiac activity, yolk sac presence, adnexal mass size, and patient age, did not show a significant relationship in this model. The median time to surgical intervention in failed cases was 7\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Single-dose MTX remains a safe and effective option for carefully selected patients with relatively contraindicated ectopic pregnancies, achieving a 65.5% success rate. High baseline \u03b2-hCG and pelvic free fluid may serve as predictors of treatment failure, but do not preclude medical management when close monitoring is ensured. The proposed scoring system should be considered exploratory and requires external validation before clinical implementation. Further prospective studies are needed to confirm these findings and better define candidates for MTX therapy in high-risk cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-026-08501-4","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:54:52Z","timestamp":1783763692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methotrexate in relatively contraindicated ectopic pregnancies: who benefits from treatment?"],"prefix":"10.1007","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7741-3681","authenticated-orcid":false,"given":"G\u00fclhan","family":"\u00d6z\u00fcm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3033-985X","authenticated-orcid":false,"given":"Hakan","family":"G\u00fcraslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-4487","authenticated-orcid":false,"given":"Nur\u015fen","family":"Kurto\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-9116","authenticated-orcid":false,"given":"Levent","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"8501_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejogrb.2020.10.036","volume":"255","author":"A Goh","year":"2020","unstructured":"Goh A, Karine P, Kirby A, Williams C, Kapurubandara S (2020) Day 1 to day 4 serum hCG change in predicting single-dose methotrexate treatment failure for tubal ectopic pregnancies. Eur J Obstet Gynecol Reprod Biol 255:105\u2013110. https:\/\/doi.org\/10.1016\/j.ejogrb.2020.10.036","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"8501_CR2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/IJWH.S279426","volume":"12","author":"AM Sindiani","year":"2020","unstructured":"Sindiani AM, Alshdaifat E, Obeidat B, Obeidat R, Rawashdeh H, Yaseen H (2020) The use of single dose methotrexate in the management of ectopic pregnancy and pregnancy of unknown location: 10\u00a0years\u2019 experience in a tertiary center. Int J Women\u2019s Health 12:1233\u20131239. https:\/\/doi.org\/10.2147\/IJWH.S279426","journal-title":"Int J Women's Health"},{"issue":"3","key":"8501_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00404-025-08069-5","volume":"312","author":"A Darwish","year":"2025","unstructured":"Darwish A, Avishalom S, Sgayer I, Mikhail SM, Lowenstein L, Aiob A (2025) Distinguishing tubal rupture from tubal abortion in ectopic pregnancies after methotrexate treatment: a retrospective cohort study. Arch Gynecol Obstet 312(3):833\u2013839. https:\/\/doi.org\/10.1007\/s00404-025-08069-5","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"8501_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268741","volume":"17","author":"MJ Davenport","year":"2022","unstructured":"Davenport MJ, Lindquist A, Brownfoot F, Pritchard N, Tong S, Hastie R (2022) Time to resolution of tubal ectopic pregnancy following methotrexate treatment: a retrospective cohort study. PLoS ONE 17(5):e0268741. https:\/\/doi.org\/10.1371\/journal.pone.0268741","journal-title":"PLoS ONE"},{"issue":"2","key":"8501_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3892\/etm.2021.11073","volume":"23","author":"C Grigoriu","year":"2022","unstructured":"Grigoriu C, Bohiltea RE, Mihai BM, Zugravu CA, Furtunescu F, Georgescu TA, Munteanu DI (2022) Success rate of methotrexate in the conservative treatment of tubal ectopic pregnancies. Exp Ther Med 23(2):150. https:\/\/doi.org\/10.3892\/etm.2021.11073","journal-title":"Exp Ther Med"},{"issue":"1","key":"8501_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1186\/s12884-024-07122-6","volume":"24","author":"L Fu","year":"2024","unstructured":"Fu L, Liu X, Tian Z, Du Z, Wang X, Wang X, Li X, Xu T, Sun Z (2024) Risk factors for methotrexate treatment failure in tubal ectopic pregnancy: a retrospective cohort study. BMC Pregnancy Childbirth 24(1):884. https:\/\/doi.org\/10.1186\/s12884-024-07122-6","journal-title":"BMC Pregnancy Childbirth"},{"issue":"4","key":"8501_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.38053\/acmj.1179420","volume":"4","author":"AA Madenli","year":"2022","unstructured":"Madenli AA, \u00d6zt\u00fcrk H\u00c7 (2022) The evaluation of success and failure of methotrexate treatment in ectopic pregnancy. Anatol Curr Med J 4(4):449\u2013454. https:\/\/doi.org\/10.38053\/acmj.1179420","journal-title":"Anatol Curr Med J"},{"issue":"50","key":"8501_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027851","volume":"100","author":"C Xiao","year":"2021","unstructured":"Xiao C, Shi Q, Cheng Q, Xu J (2021) Non-surgical management of tubal ectopic pregnancy: a systematic review and meta-analysis. Med 100(50):e27851. https:\/\/doi.org\/10.1097\/MD.0000000000027851","journal-title":"Med"},{"issue":"7","key":"8501_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/humrep\/dead089","volume":"38","author":"SC Mackenzie","year":"2023","unstructured":"Mackenzie SC, Moakes CA, Doust AM, Mol BW, Duncan WC, Tong S, Horne AW, Whitaker LHR (2023) Early (Days 1\u20134) post-treatment serum hCG level changes predict single-dose methotrexate treatment success in tubal ectopic pregnancy. Hum reproduc (Oxford, England) 38(7):1261\u20131267. https:\/\/doi.org\/10.1093\/humrep\/dead089","journal-title":"Hum reproduc (Oxford, England)"},{"issue":"Suppl 1","key":"8501_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s13224-024-01980-y","volume":"75","author":"L Yi","year":"2025","unstructured":"Yi L, Huang W, Liu Q, Huang Y, Liu Y (2025) Construction and validation of a clinical prediction model for predicting tubal pregnancy rupture based on nomogram. J Obstet Gynaecol India 75(Suppl 1):300\u2013309. https:\/\/doi.org\/10.1007\/s13224-024-01980-y","journal-title":"J Obstet Gynaecol India"},{"issue":"2","key":"8501_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ijgo.15927","volume":"168","author":"G Zeevi","year":"2025","unstructured":"Zeevi G, Bercovich O, Haring Y, Nahum S, Romano A, Houri O, Yeoshoua E, Eitan R, Peled Y, Krissi H (2025) Nomogram to predict methotrexate treatment success in ectopic pregnancy. Int J Gynaecol obstet: official organ Int Fed Gynaecol Obstet 168(2):620\u2013627. https:\/\/doi.org\/10.1002\/ijgo.15927","journal-title":"Int J Gynaecol obstet: official organ Int Fed Gynaecol Obstet"},{"issue":"5","key":"8501_CR12","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00404-024-07747-0","volume":"310","author":"FB F\u0131ratl\u0131gil","year":"2024","unstructured":"F\u0131ratl\u0131gil FB, Sucu S, Sucu ST, Ozkan MA, Reis YA, Dereli ML, Ozkan S, Engin-Ustun Y (2024) Comparison of 2\u00a0year reproductive outcomes of tubal ectopic pregnancies treated with surgery, methotrexate or expectant management. Arch Gynecol Obstet 310(5):2561\u20132568. https:\/\/doi.org\/10.1007\/s00404-024-07747-0","journal-title":"Arch Gynecol Obstet"},{"key":"8501_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejogrb.2023.04.030","volume":"285","author":"A Aiob","year":"2023","unstructured":"Aiob A, Yousef H, Abu Shqara R, Mustafa Mikhail S, Odeh M, Lowenstein L (2023) Risk factors and prediction of ectopic pregnancy rupture following methotrexate treatment: a retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 285:181\u2013185. https:\/\/doi.org\/10.1016\/j.ejogrb.2023.04.030","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"8501_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12884-020-03350-8","volume":"20","author":"J Zhang","year":"2020","unstructured":"Zhang J, Zhang Y, Gan L, Liu XY, Du SP (2020) Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy. BMC Pregnancy Childbirth 20(1):654. https:\/\/doi.org\/10.1186\/s12884-020-03350-8","journal-title":"BMC Pregnancy Childbirth"},{"issue":"7","key":"8501_CR15","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.jmig.2020.09.003","volume":"28","author":"JA Gingold","year":"2021","unstructured":"Gingold JA, Janmey I, Gemmell L, Mei L, Falcone T (2021) Effect of methotrexate on salpingostomy completion rate for tubal ectopic pregnancy: a retrospective cohort study. J Minim Invasive Gynecol 28(7):1334-1342.e3. https:\/\/doi.org\/10.1016\/j.jmig.2020.09.003","journal-title":"J Minim Invasive Gynecol"},{"issue":"1","key":"8501_CR16","doi-asserted-by":"publisher","first-page":"2361456","DOI":"10.1080\/01443615.2024.2361456","volume":"44","author":"E Abdelfattah-Arafa","year":"2024","unstructured":"Abdelfattah-Arafa E, Abdussalam HF, Omar Saad M, El Ansari W (2024) The predictors of successful methotrexate treatment of tubal ectopic pregnancy. J Obstet Gynaecol 44(1):2361456. https:\/\/doi.org\/10.1080\/01443615.2024.2361456","journal-title":"J Obstet Gynaecol"},{"issue":"5","key":"8501_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/jog.15923","volume":"50","author":"S Deniz","year":"2024","unstructured":"Deniz S, Ali B, Canan U, Y\u0131lmaz AH, Olcay I, Burcu D, Fatma GK (2024) Evaluation of the parameters in predicting single-dose methotrexate therapy success for ectopic pregnancy. J Obstet Gynaecol Res 50(5):856\u2013863. https:\/\/doi.org\/10.1111\/jog.15923","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"8501_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.fertnstert.2013.06.013","volume":"100","author":"Practice Committee of American Society for Reproductive Medicine","year":"2013","unstructured":"Practice Committee of American Society for Reproductive Medicine (2013) Medical treatment of ectopic pregnancy: a committee opinion. Fertil Steril 100(3):638\u2013644. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.06.013","journal-title":"Fertil Steril"},{"issue":"6 Pt 1","key":"8501_CR19","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/0002-9378(93)90687-e","volume":"168","author":"TG Stovall","year":"1993","unstructured":"Stovall TG, Ling FW (1993) Single-dose methotrexate: an expanded clinical trial. Am J Obstet Gynecol 168(6 Pt 1):1759\u20131765. https:\/\/doi.org\/10.1016\/0002-9378(93)90687-e","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"8501_CR20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/ijgo.15511","volume":"166","author":"A Dayan-Schwartz","year":"2024","unstructured":"Dayan-Schwartz A, Abd Elgani S, Abdul-Ghani T, Kogan L, Reiss A, Tal A (2024) Pharmacological treatment of ectopic pregnancy: Accuracy, safety and cost-effectiveness of day 1\u20137 \u03b2-hCG measurements. Int J Gynecol Obstet 166(3):1330\u20131336. https:\/\/doi.org\/10.1002\/ijgo.15511","journal-title":"Int J Gynecol Obstet"},{"issue":"26","key":"8501_CR21","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1056\/NEJM199912233412604","volume":"341","author":"GH Lipscomb","year":"1999","unstructured":"Lipscomb GH, McCord ML, Stovall TG, Huff G, Portera SG, Ling FW (1999) Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 341(26):1974\u20131978. https:\/\/doi.org\/10.1056\/NEJM199912233412604","journal-title":"N Engl J Med"},{"issue":"3","key":"8501_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0015-0282(16)60549-6","volume":"51","author":"TG Stovall","year":"1989","unstructured":"Stovall TG, Ling FW, Buster JE (1989) Outpatient chemotherapy of unruptured ectopic pregnancy. Fertil Steril 51(3):435\u2013438","journal-title":"Fertil Steril"},{"issue":"4","key":"8501_CR23","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s43032-022-00881-7","volume":"29","author":"A Cohen","year":"2022","unstructured":"Cohen A, Bar-On S, Cohen Y, Sandel O, Fouks Y, Michaan N, Tzur T, Levin I (2022) Ruptured ectopic pregnancies following methotrexate treatment: clinical course and predictors for improving patient counseling. Reprod Sci 29(4):1209\u20131214","journal-title":"Reprod Sci"},{"key":"8501_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejogrb.2020.02.029","volume":"247","author":"M Leonardi","year":"2020","unstructured":"Leonardi M, Allison E, Lu C, Nadim B, Condous G (2020) Prognostic accuracy of a novel methotrexate protocol for the resolution of tubal ectopic pregnancies. Eur J Obstet Gynecol Reprod Biol 247:186\u2013190","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7","key":"8501_CR25","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.fertnstert.2009.09.014","volume":"93","author":"O Balci","year":"2010","unstructured":"Balci O, Ozdemir S, Mahmoud AS, Acar A, Colakoglu MC (2010) The efficacy of multiple-dose methotrexate treatment for unruptured tubal ectopic pregnancy and conversion rate to surgery: a study on 294 cases. Fertil Steril 93(7):2415\u20132417","journal-title":"Fertil Steril"},{"issue":"1","key":"8501_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2024.2447997","volume":"45","author":"L Tang","year":"2025","unstructured":"Tang L, Nie S, Ling L, Zhu Q (2025) Predictors of treatment failure of tubal pregnancy with single-dose methotrexate regimen - a systematic review and meta-analysis. J Obstet Gynaecol 45(1):2447997. https:\/\/doi.org\/10.1080\/01443615.2024.2447997","journal-title":"J Obstet Gynaecol"},{"issue":"3","key":"8501_CR27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.fertnstert.2006.10.007","volume":"87","author":"S Menon","year":"2007","unstructured":"Menon S, Colins J, Barnhart KT (2007) Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 87(3):481\u2013484. https:\/\/doi.org\/10.1016\/j.fertnstert.2006.10.007","journal-title":"Fertil Steril"},{"issue":"5","key":"8501_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ajo.12257","volume":"54","author":"M Atkinson","year":"2014","unstructured":"Atkinson M, Gupta S, Mcgee T (2014) \u03b2hCG monitoring after single-dose methotrexate treatment of tubal ectopic pregnancy: is the day 4 \u03b2hCG necessary? A retrospective cohort study. Aust N Z J Obstet Gynaecol 54(5):475\u2013479. https:\/\/doi.org\/10.1111\/ajo.12257","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"7","key":"8501_CR29","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/jog.14259","volume":"46","author":"N Shatkin Hamish","year":"2020","unstructured":"Shatkin Hamish N, Wolf M, Tendler R, Sharon A, Bornstein J, Odeh M (2020) Early prediction of methotrexate treatment outcome in tubal ectopic pregnancy based on days 0 and 4 human chorionic gonadotropin levels. J Obstet Gynaecol Res 46(7):1104\u20131109. https:\/\/doi.org\/10.1111\/jog.14259","journal-title":"J Obstet Gynaecol Res"},{"issue":"6","key":"8501_CR30","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/01443615.2019.1575344","volume":"39","author":"AGK Kanmaz","year":"2019","unstructured":"Kanmaz AGK, Hamdi \u0130nan A, Beyan E, Budak A (2019) Various BhCG monitoring protocols for predicting the success of single-dose methotrexate in the treatment of ectopic pregnancy. J Obstet Gynaecol 39(6):811\u2013815. https:\/\/doi.org\/10.1080\/01443615.2019.1575344","journal-title":"J Obstet Gynaecol"},{"issue":"3","key":"8501_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.mefs.2014.11.001","volume":"20","author":"AH Shaamash","year":"2015","unstructured":"Shaamash AH, Alshahrani MS, Awadalla NJ, Hakami HW (2015) Falling in serum \u03b2 human chorionic gonadotropin levels between days 1 and 7 as a new protocol to predict successful single-dose of methotrexate therapy for ectopic pregnancy. Middle East Fertility Soc J 20(3):159\u2013164","journal-title":"Middle East Fertility Soc J"},{"issue":"7","key":"8501_CR32","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jmig.2017.07.025","volume":"24","author":"Y Dai","year":"2017","unstructured":"Dai Y, Zhang G, Zhu L, Lang J, Liu Z (2017) Routine \u03b2-Human chorionic gonadotropin monitoring for single-dose methotrexate treatment in ectopic pregnancy. J Minim Invasive Gynecol 24(7):1195\u20131199. https:\/\/doi.org\/10.1016\/j.jmig.2017.07.025","journal-title":"J Minim Invasive Gynecol"},{"issue":"5","key":"8501_CR33","first-page":"754","volume":"77","author":"TG Stovall","year":"1991","unstructured":"Stovall TG, Ling FW, Gray LA (1991) Single-dose methotrexate for treatment of ectopic pregnancy. Obstet Gynecol 77(5):754\u2013757","journal-title":"Obstet Gynecol"},{"key":"8501_CR34","doi-asserted-by":"publisher","unstructured":"KURTAY, S., DO\u011eAN YANGIR, G., G\u00d6Z\u00dcK\u00dc\u00c7\u00dcK, M., \u00dcST\u00dcN, Y (2024) Clinical characteristics of patients with ectopic pregnancies treated with additional doses of methotrexate. Med J Ankara Train Res Hosp 57(2) https:\/\/doi.org\/10.20492\/aeahtd.1371505","DOI":"10.20492\/aeahtd.1371505"},{"issue":"1","key":"8501_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/09513590.2018.1490406","volume":"35","author":"AP Hutchinson","year":"2019","unstructured":"Hutchinson AP, Pereira N, Chung ER, Shah NJ, Zeku M, Chung PH, Rosenwaks Z (2019) Risk factors and human chorionic gonadotropin trends in patients with ruptured tubal ectopic pregnancies despite methotrexate treatment. Gynecol Endocrinol 35(1):49\u201352. https:\/\/doi.org\/10.1080\/09513590.2018.1490406","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"8501_CR36","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/S0002-9378(98)70343-6","volume":"178","author":"GH Lipscomb","year":"1998","unstructured":"Lipscomb GH, Bran D, McCord ML, Portera JC, Ling FW (1998) Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate. Am J Obstet Gynecol 178(6):1354\u20131358","journal-title":"Am J Obstet Gynecol"},{"key":"8501_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurox.2024.100286","volume":"21","author":"F Keikha","year":"2024","unstructured":"Keikha F, Ardekani SS, Parsaei M, Zargarzadeh N, Hadizadeh A, Tarafdari A (2024) Methotrexate as the first-line treatment of unruptured tubular ectopic pregnancies with high initial human chorionic gonadotropin levels: a retrospective cohort. Eur J Obstet Gynecol Reprod Biol 21:100286. https:\/\/doi.org\/10.1016\/j.eurox.2024.100286","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"08","key":"8501_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.53350\/pjmhs22168161","volume":"16","author":"H Bibi","year":"2022","unstructured":"Bibi H, Akhter S, Saba Nasir BS (2022) Efficacy of methotrexate treatment, nonsurgical treatment of ectopic pregnancy (EP). Pakistan J Med Health Sci 16(08):161\u2013161","journal-title":"Pakistan J Med Health Sci"},{"issue":"2","key":"8501_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.fertnstert.2006.06.054","volume":"87","author":"K Barnhart","year":"2007","unstructured":"Barnhart K, Hummel AC, Sammel MD, Menon S, Jain J, Chakhtoura N (2007) Use of \u201c2-dose\u201dregimen of methotrexate to treat ectopic pregnancy. Fertil Steril 87(2):250\u2013256. https:\/\/doi.org\/10.1016\/j.fertnstert.2006.06.054","journal-title":"Fertil Steril"},{"issue":"5","key":"8501_CR40","doi-asserted-by":"publisher","first-page":"403","DOI":"10.18502\/ijrm.v21i5.13475","volume":"21","author":"A Tarafdari","year":"2023","unstructured":"Tarafdari A, Bandarian M, Hantoushzadeh S, Hadizadeh A, Shahsavari S, Alsadat Razavi M (2023) Assessing the risk factors and management outcomes of ectopic pregnancy: a retrospective case-control study. Int J Reprod BioMed (IJRM) 21(5):403\u2013414. https:\/\/doi.org\/10.18502\/ijrm.v21i5.13475","journal-title":"Int J Reprod BioMed (IJRM)"},{"issue":"2","key":"8501_CR41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ajog.2019.01.002","volume":"221","author":"S Alur-Gupta","year":"2019","unstructured":"Alur-Gupta S, Cooney LG, Senapati S, Sammel MD, Barnhart KT (2019) Two-dose versus single-dose methotrexate for treatment of ectopic pregnancy: a meta-analysis. Am J Obstet Gynecol 221(2):95-108.e2. https:\/\/doi.org\/10.1016\/j.ajog.2019.01.002","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"8501_CR42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1080\/01443615.2017.1312308","volume":"37","author":"H Qayyum","year":"2017","unstructured":"Qayyum H, Ramlakhan S, Keriakos R, Gunasekaran B (2017) Ruptured ectopic pregnancy with a negative urinary pregnancy test after methotrexate treatment - challenges of diagnosis in the emergency department. J Obstet Gynaecol 37(7):958\u2013959. https:\/\/doi.org\/10.1080\/01443615.2017.1312308","journal-title":"J Obstet Gynaecol"},{"issue":"5","key":"8501_CR43","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00404-024-07458-6","volume":"309","author":"AS Yeniocak","year":"2024","unstructured":"Yeniocak AS, Tercan C, Dagdeviren E, Arabac\u0131 O, Genc EE (2024) Evaluation of a scoring system to predict treatment success with single-dose methotrexate in ectopic pregnancy. Arch Gynecol Obstet 309(5):2047\u20132055. https:\/\/doi.org\/10.1007\/s00404-024-07458-6","journal-title":"Arch Gynecol Obstet"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08501-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:37:19Z","timestamp":1785847039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08501-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8501"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08501-4","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of the University of Health Sciences \u0130stanbul Ba\u011fc\u0131lar Training and Research Hospital in 2025 (Approval No: 2025\/05\/01\/044) and was officially registered. All procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective design of the study, the requirement for informed consent was waived by the Institutional Ethics Committee.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"239"}}